Time interval between diagnosis to treatment of breast cancer and the impact of health insurance coverage: a sub analysis of the AMAZONA III Study (GBECAM 0115)
Purpose Breast cancer (BC) is the most common type of cancer among women in Brazil. Evidence shows that delayed treatment onset is associated with increased mortality. This study aimed to evaluate median days between diagnosis and treatment and factors associated with delayed start of treatment (>...
Gespeichert in:
| Veröffentlicht in: | Breast cancer research and treatment 2023-02, Vol.198 (1), p.123-130 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 130 |
|---|---|
| container_issue | 1 |
| container_start_page | 123 |
| container_title | Breast cancer research and treatment |
| container_volume | 198 |
| creator | Maschmann, Raíra Mesquita De Jesus, Rafaela Gomes Werutsky, Gustavo Rebelatto, Taiane Francieli Queiroz, Geraldo Simon, Sergio Daniel Bines, José Barrios, Carlos Henrique Escosteguy Rosa, Daniela Dornelles |
| description | Purpose
Breast cancer (BC) is the most common type of cancer among women in Brazil. Evidence shows that delayed treatment onset is associated with increased mortality. This study aimed to evaluate median days between diagnosis and treatment and factors associated with delayed start of treatment (> 60 days after diagnosis): stage, treatment received, subtype, epidemiological characteristics, and type of healthcare coverage.
Methods
This analysis included 1709 stage I–III BC patients from AMAZONA III, a prospective, observational study, diagnosed from January 2016 to March 2018 in 22 centers in Brazil.
Results
The median number of days from diagnosis to beginning of first oncologic treatment was 46 days (IQR 28–75) overall, 43 days (IQR 25–75) for stage I disease, 49 days (IQR 28–81) for stage II, and 44 days (IQR 30–68) for stage III, (
p
= 0.1180). According to first treatment received, diagnosis-to-treatment interval was 43 days (IQR 29–65) for neoadjuvant chemotherapy and 48 days (IQR 26–81) for surgery. Diagnosis-to-treatment interval was higher in women treated in the public system versus the private system (56 vs. 34 days,
p
|
| doi_str_mv | 10.1007/s10549-022-06809-8 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_2759957698</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A734965656</galeid><sourcerecordid>A734965656</sourcerecordid><originalsourceid>FETCH-LOGICAL-c473t-7cce26b7ad9c18d3fa5db12f112b7162973ec9651d10e1d7052dfa189a5f13383</originalsourceid><addsrcrecordid>eNp9ks1u1DAUhSMEokPhBVggS0ioLFL8M45jdmFUykgtXVA2bCzHvplJlcRT2ymat-FRcZpCKULIC8u-3znysU6WvST4mGAs3gWC-VLmmNIcFyWWefkoWxAuWC4oEY-zBSaFyNOkOMiehXCFMZYCy6fZASt4WWBWLrIfl20PqB0i-BvdoRrid4AB2VZvBhfagKJD0YOOPQwRuQbV6RAiMnow4JEeLIrbZNDvtLmdb0F3cZscw-gnBhl3A15v4D3SKIx1kuhuPzkneJJW59W3i88VWq_X6Esc7R4dnX44WVXnCBPC3z7PnjS6C_Dibj_Mvn48uVx9ys8uTter6iw3S8FiLowBWtRCW2lIaVmjua0JbQihtSAFlYKBkQUnlmAgVmBObaNJKTVvCGMlO8yOZt-dd9cjhKj6NhjoOj2AG4OigkvJRSEn9PVf6JUbfYo1UQKTBHF6T210B6odGhe9NpOpqgRbpreklajjf1BpWehb4wZo2nT_QPDmD8H828F1Y2zdEB6CdAaNdyF4aNTOt732e0Wwmvqj5v6o1B912x81RXt1F22se7C_Jb8KkwA2AyGNhg34--z_sf0JKoLMig</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2770176952</pqid></control><display><type>article</type><title>Time interval between diagnosis to treatment of breast cancer and the impact of health insurance coverage: a sub analysis of the AMAZONA III Study (GBECAM 0115)</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Maschmann, Raíra Mesquita ; De Jesus, Rafaela Gomes ; Werutsky, Gustavo ; Rebelatto, Taiane Francieli ; Queiroz, Geraldo ; Simon, Sergio Daniel ; Bines, José ; Barrios, Carlos Henrique Escosteguy ; Rosa, Daniela Dornelles</creator><creatorcontrib>Maschmann, Raíra Mesquita ; De Jesus, Rafaela Gomes ; Werutsky, Gustavo ; Rebelatto, Taiane Francieli ; Queiroz, Geraldo ; Simon, Sergio Daniel ; Bines, José ; Barrios, Carlos Henrique Escosteguy ; Rosa, Daniela Dornelles</creatorcontrib><description>Purpose
Breast cancer (BC) is the most common type of cancer among women in Brazil. Evidence shows that delayed treatment onset is associated with increased mortality. This study aimed to evaluate median days between diagnosis and treatment and factors associated with delayed start of treatment (> 60 days after diagnosis): stage, treatment received, subtype, epidemiological characteristics, and type of healthcare coverage.
Methods
This analysis included 1709 stage I–III BC patients from AMAZONA III, a prospective, observational study, diagnosed from January 2016 to March 2018 in 22 centers in Brazil.
Results
The median number of days from diagnosis to beginning of first oncologic treatment was 46 days (IQR 28–75) overall, 43 days (IQR 25–75) for stage I disease, 49 days (IQR 28–81) for stage II, and 44 days (IQR 30–68) for stage III, (
p
= 0.1180). According to first treatment received, diagnosis-to-treatment interval was 43 days (IQR 29–65) for neoadjuvant chemotherapy and 48 days (IQR 26–81) for surgery. Diagnosis-to-treatment interval was higher in women treated in the public system versus the private system (56 vs. 34 days,
p
< 0.0001). Patients in the public system had an increased odds of delayed treatment initiation (OR 4.74 95% CI 3.09–7.26,
p
< .0001). The longer interval from diagnosis to treatment in the public system was independent of clinical stage, type of treatment (systemic vs surgery first), subtype and region of the country.
Conclusion
By characterizing the delays in care delivery, our study will aid stakeholders to better design interventions and allocate resource to improve timely treatment for breast cancer in Brazil.
ClinicalTrials.gov Identifier: NCT02663973, registered on January, 26th, 2016.</description><identifier>ISSN: 0167-6806</identifier><identifier>EISSN: 1573-7217</identifier><identifier>DOI: 10.1007/s10549-022-06809-8</identifier><identifier>PMID: 36586038</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Amazona ; Analysis ; Animals ; Breast cancer ; Breast Neoplasms - diagnosis ; Breast Neoplasms - epidemiology ; Breast Neoplasms - therapy ; Cancer ; Chemotherapy ; Diagnosis ; Disease-Free Survival ; Drug therapy ; Epidemiology ; Female ; Humans ; Insurance Coverage ; Medicine ; Medicine & Public Health ; Neoplasm Staging ; Oncology ; Patients ; Prospective Studies ; Surgery</subject><ispartof>Breast cancer research and treatment, 2023-02, Vol.198 (1), p.123-130</ispartof><rights>The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.</rights><rights>2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.</rights><rights>COPYRIGHT 2023 Springer</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c473t-7cce26b7ad9c18d3fa5db12f112b7162973ec9651d10e1d7052dfa189a5f13383</citedby><cites>FETCH-LOGICAL-c473t-7cce26b7ad9c18d3fa5db12f112b7162973ec9651d10e1d7052dfa189a5f13383</cites><orcidid>0000-0002-6196-1919</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s10549-022-06809-8$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s10549-022-06809-8$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,777,781,27905,27906,41469,42538,51300</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36586038$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Maschmann, Raíra Mesquita</creatorcontrib><creatorcontrib>De Jesus, Rafaela Gomes</creatorcontrib><creatorcontrib>Werutsky, Gustavo</creatorcontrib><creatorcontrib>Rebelatto, Taiane Francieli</creatorcontrib><creatorcontrib>Queiroz, Geraldo</creatorcontrib><creatorcontrib>Simon, Sergio Daniel</creatorcontrib><creatorcontrib>Bines, José</creatorcontrib><creatorcontrib>Barrios, Carlos Henrique Escosteguy</creatorcontrib><creatorcontrib>Rosa, Daniela Dornelles</creatorcontrib><title>Time interval between diagnosis to treatment of breast cancer and the impact of health insurance coverage: a sub analysis of the AMAZONA III Study (GBECAM 0115)</title><title>Breast cancer research and treatment</title><addtitle>Breast Cancer Res Treat</addtitle><addtitle>Breast Cancer Res Treat</addtitle><description>Purpose
Breast cancer (BC) is the most common type of cancer among women in Brazil. Evidence shows that delayed treatment onset is associated with increased mortality. This study aimed to evaluate median days between diagnosis and treatment and factors associated with delayed start of treatment (> 60 days after diagnosis): stage, treatment received, subtype, epidemiological characteristics, and type of healthcare coverage.
Methods
This analysis included 1709 stage I–III BC patients from AMAZONA III, a prospective, observational study, diagnosed from January 2016 to March 2018 in 22 centers in Brazil.
Results
The median number of days from diagnosis to beginning of first oncologic treatment was 46 days (IQR 28–75) overall, 43 days (IQR 25–75) for stage I disease, 49 days (IQR 28–81) for stage II, and 44 days (IQR 30–68) for stage III, (
p
= 0.1180). According to first treatment received, diagnosis-to-treatment interval was 43 days (IQR 29–65) for neoadjuvant chemotherapy and 48 days (IQR 26–81) for surgery. Diagnosis-to-treatment interval was higher in women treated in the public system versus the private system (56 vs. 34 days,
p
< 0.0001). Patients in the public system had an increased odds of delayed treatment initiation (OR 4.74 95% CI 3.09–7.26,
p
< .0001). The longer interval from diagnosis to treatment in the public system was independent of clinical stage, type of treatment (systemic vs surgery first), subtype and region of the country.
Conclusion
By characterizing the delays in care delivery, our study will aid stakeholders to better design interventions and allocate resource to improve timely treatment for breast cancer in Brazil.
ClinicalTrials.gov Identifier: NCT02663973, registered on January, 26th, 2016.</description><subject>Amazona</subject><subject>Analysis</subject><subject>Animals</subject><subject>Breast cancer</subject><subject>Breast Neoplasms - diagnosis</subject><subject>Breast Neoplasms - epidemiology</subject><subject>Breast Neoplasms - therapy</subject><subject>Cancer</subject><subject>Chemotherapy</subject><subject>Diagnosis</subject><subject>Disease-Free Survival</subject><subject>Drug therapy</subject><subject>Epidemiology</subject><subject>Female</subject><subject>Humans</subject><subject>Insurance Coverage</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Neoplasm Staging</subject><subject>Oncology</subject><subject>Patients</subject><subject>Prospective Studies</subject><subject>Surgery</subject><issn>0167-6806</issn><issn>1573-7217</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp9ks1u1DAUhSMEokPhBVggS0ioLFL8M45jdmFUykgtXVA2bCzHvplJlcRT2ymat-FRcZpCKULIC8u-3znysU6WvST4mGAs3gWC-VLmmNIcFyWWefkoWxAuWC4oEY-zBSaFyNOkOMiehXCFMZYCy6fZASt4WWBWLrIfl20PqB0i-BvdoRrid4AB2VZvBhfagKJD0YOOPQwRuQbV6RAiMnow4JEeLIrbZNDvtLmdb0F3cZscw-gnBhl3A15v4D3SKIx1kuhuPzkneJJW59W3i88VWq_X6Esc7R4dnX44WVXnCBPC3z7PnjS6C_Dibj_Mvn48uVx9ys8uTter6iw3S8FiLowBWtRCW2lIaVmjua0JbQihtSAFlYKBkQUnlmAgVmBObaNJKTVvCGMlO8yOZt-dd9cjhKj6NhjoOj2AG4OigkvJRSEn9PVf6JUbfYo1UQKTBHF6T210B6odGhe9NpOpqgRbpreklajjf1BpWehb4wZo2nT_QPDmD8H828F1Y2zdEB6CdAaNdyF4aNTOt732e0Wwmvqj5v6o1B912x81RXt1F22se7C_Jb8KkwA2AyGNhg34--z_sf0JKoLMig</recordid><startdate>20230201</startdate><enddate>20230201</enddate><creator>Maschmann, Raíra Mesquita</creator><creator>De Jesus, Rafaela Gomes</creator><creator>Werutsky, Gustavo</creator><creator>Rebelatto, Taiane Francieli</creator><creator>Queiroz, Geraldo</creator><creator>Simon, Sergio Daniel</creator><creator>Bines, José</creator><creator>Barrios, Carlos Henrique Escosteguy</creator><creator>Rosa, Daniela Dornelles</creator><general>Springer US</general><general>Springer</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>K9-</scope><scope>K9.</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-6196-1919</orcidid></search><sort><creationdate>20230201</creationdate><title>Time interval between diagnosis to treatment of breast cancer and the impact of health insurance coverage: a sub analysis of the AMAZONA III Study (GBECAM 0115)</title><author>Maschmann, Raíra Mesquita ; De Jesus, Rafaela Gomes ; Werutsky, Gustavo ; Rebelatto, Taiane Francieli ; Queiroz, Geraldo ; Simon, Sergio Daniel ; Bines, José ; Barrios, Carlos Henrique Escosteguy ; Rosa, Daniela Dornelles</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c473t-7cce26b7ad9c18d3fa5db12f112b7162973ec9651d10e1d7052dfa189a5f13383</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Amazona</topic><topic>Analysis</topic><topic>Animals</topic><topic>Breast cancer</topic><topic>Breast Neoplasms - diagnosis</topic><topic>Breast Neoplasms - epidemiology</topic><topic>Breast Neoplasms - therapy</topic><topic>Cancer</topic><topic>Chemotherapy</topic><topic>Diagnosis</topic><topic>Disease-Free Survival</topic><topic>Drug therapy</topic><topic>Epidemiology</topic><topic>Female</topic><topic>Humans</topic><topic>Insurance Coverage</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Neoplasm Staging</topic><topic>Oncology</topic><topic>Patients</topic><topic>Prospective Studies</topic><topic>Surgery</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Maschmann, Raíra Mesquita</creatorcontrib><creatorcontrib>De Jesus, Rafaela Gomes</creatorcontrib><creatorcontrib>Werutsky, Gustavo</creatorcontrib><creatorcontrib>Rebelatto, Taiane Francieli</creatorcontrib><creatorcontrib>Queiroz, Geraldo</creatorcontrib><creatorcontrib>Simon, Sergio Daniel</creatorcontrib><creatorcontrib>Bines, José</creatorcontrib><creatorcontrib>Barrios, Carlos Henrique Escosteguy</creatorcontrib><creatorcontrib>Rosa, Daniela Dornelles</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Breast cancer research and treatment</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Maschmann, Raíra Mesquita</au><au>De Jesus, Rafaela Gomes</au><au>Werutsky, Gustavo</au><au>Rebelatto, Taiane Francieli</au><au>Queiroz, Geraldo</au><au>Simon, Sergio Daniel</au><au>Bines, José</au><au>Barrios, Carlos Henrique Escosteguy</au><au>Rosa, Daniela Dornelles</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Time interval between diagnosis to treatment of breast cancer and the impact of health insurance coverage: a sub analysis of the AMAZONA III Study (GBECAM 0115)</atitle><jtitle>Breast cancer research and treatment</jtitle><stitle>Breast Cancer Res Treat</stitle><addtitle>Breast Cancer Res Treat</addtitle><date>2023-02-01</date><risdate>2023</risdate><volume>198</volume><issue>1</issue><spage>123</spage><epage>130</epage><pages>123-130</pages><issn>0167-6806</issn><eissn>1573-7217</eissn><abstract>Purpose
Breast cancer (BC) is the most common type of cancer among women in Brazil. Evidence shows that delayed treatment onset is associated with increased mortality. This study aimed to evaluate median days between diagnosis and treatment and factors associated with delayed start of treatment (> 60 days after diagnosis): stage, treatment received, subtype, epidemiological characteristics, and type of healthcare coverage.
Methods
This analysis included 1709 stage I–III BC patients from AMAZONA III, a prospective, observational study, diagnosed from January 2016 to March 2018 in 22 centers in Brazil.
Results
The median number of days from diagnosis to beginning of first oncologic treatment was 46 days (IQR 28–75) overall, 43 days (IQR 25–75) for stage I disease, 49 days (IQR 28–81) for stage II, and 44 days (IQR 30–68) for stage III, (
p
= 0.1180). According to first treatment received, diagnosis-to-treatment interval was 43 days (IQR 29–65) for neoadjuvant chemotherapy and 48 days (IQR 26–81) for surgery. Diagnosis-to-treatment interval was higher in women treated in the public system versus the private system (56 vs. 34 days,
p
< 0.0001). Patients in the public system had an increased odds of delayed treatment initiation (OR 4.74 95% CI 3.09–7.26,
p
< .0001). The longer interval from diagnosis to treatment in the public system was independent of clinical stage, type of treatment (systemic vs surgery first), subtype and region of the country.
Conclusion
By characterizing the delays in care delivery, our study will aid stakeholders to better design interventions and allocate resource to improve timely treatment for breast cancer in Brazil.
ClinicalTrials.gov Identifier: NCT02663973, registered on January, 26th, 2016.</abstract><cop>New York</cop><pub>Springer US</pub><pmid>36586038</pmid><doi>10.1007/s10549-022-06809-8</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0002-6196-1919</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0167-6806 |
| ispartof | Breast cancer research and treatment, 2023-02, Vol.198 (1), p.123-130 |
| issn | 0167-6806 1573-7217 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2759957698 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Amazona Analysis Animals Breast cancer Breast Neoplasms - diagnosis Breast Neoplasms - epidemiology Breast Neoplasms - therapy Cancer Chemotherapy Diagnosis Disease-Free Survival Drug therapy Epidemiology Female Humans Insurance Coverage Medicine Medicine & Public Health Neoplasm Staging Oncology Patients Prospective Studies Surgery |
| title | Time interval between diagnosis to treatment of breast cancer and the impact of health insurance coverage: a sub analysis of the AMAZONA III Study (GBECAM 0115) |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-18T01%3A00%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Time%20interval%20between%20diagnosis%20to%20treatment%20of%20breast%20cancer%20and%20the%20impact%20of%20health%20insurance%20coverage:%20a%20sub%20analysis%20of%20the%20AMAZONA%20III%20Study%20(GBECAM%200115)&rft.jtitle=Breast%20cancer%20research%20and%20treatment&rft.au=Maschmann,%20Ra%C3%ADra%20Mesquita&rft.date=2023-02-01&rft.volume=198&rft.issue=1&rft.spage=123&rft.epage=130&rft.pages=123-130&rft.issn=0167-6806&rft.eissn=1573-7217&rft_id=info:doi/10.1007/s10549-022-06809-8&rft_dat=%3Cgale_proqu%3EA734965656%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2770176952&rft_id=info:pmid/36586038&rft_galeid=A734965656&rfr_iscdi=true |